Asia-Pacific Orthobiologics Market Forecast 2017-2025

Asia-Pacific Orthobiologics Market Forecast 2017-2025

  • July 2017 •
  • 74 pages •
  • Report ID: 4844189 •
  • Format: PDF
KEY FINDINGS
The Asia Pacific orthobiologics market is expected to grow $2590 million by 2025. The market growth is expected at the CAGR of 7.09% in the forecast period. For the market study, the base year considered is 2016. Growing need for orthobiologics products in the region is up surging the growth of the Asia-Pacific orthobiologics market.

MARKET INSIGHTS
The Asia Pacific orthobiologics market is segmented on the basis of end-user, application, product, and geography. End-user market segmented into hospitals and clinics. The application segment is further classified into spinal fusion, trauma repair, and reconstructive surgery. The Asia-Pacific market of orthobiologics by product is further segmented into demineralized bone matrix (DBM), Bone morphogenetic protein (BMP), viscosupplementation, synthetic bone graft substitutes, and stem cell therapy.

The Asia-Pacific orthobiologics market of geography is further segmented into India, China, Japan, Australia and rest of Asia-Pacific. Demand for biological implants is increasing then the mechanical implant and rise in the awareness of orthobiologics benefits is proliferating the growth of the market in this region.

COMPETETIVE INSIGHTS
Major players for the Orthobiologics market are Integra Life sciences Holding Corporation, Bioventus, Johnson& Johnson, DePuy Inc. (Acquired by Johnson and Johnson), Zimmer Biomet Inc., Exatech Inc., Mölnlycke Health Care AB, Nuvasive Inc., Globus Medical Inc., Stryker Corporation, RTI Surgical, Medtronic Inc., and Sanofi.